Recommended maintenance targeted molecular therapy regimens for metastatic disease include Olaparib, a poly (ADP ribose) polymerase (PARP) inhibitor (only for patients who have had prior platinum-based chemotherapy and carry germline BRCA1/2 mutations), and Rucaparib (for patients who have had prior platinum-based chemotherapy and carry germline or somatic BRCA1/2 mutations or PALB2 mutations). Here, BRCA1 is linked to metastatic neoplasm.